Furthermore, preclinical trials using a fully humanized anti-METCAM antibody against melanoma growth and metastasis [65, 66] and using a mouse anti-METCAM monoclonal antibody against angiogenesis and tumor growth of hepatocarcinoma, leiomyosarcoma, and pancreatic cancer [51] have been successfully demonstrated. This evidence concerns the gene MCAM and melanoma.